Drapalin and doctors network coliquio start exclusive cooperation on the topic of medical cannabis
DRAPALIN is now cooperating with coliquio, the largest German-language information platform for doctors. For the first time, 190,000 physicians have exclusive access to a new opportunity to obtain practical knowledge on the subject of medicinal cannabis and to exchange ideas together.
The use of cannabis is currently being discussed and re-evaluated in public more than ever before. This is also because the licensed distribution for consumption purposes is now planned. However, the medical significance that cannabis has acquired in recent years must not be allowed to recede in comparison, but must be expanded all the more.
By setting up the coliquio Infocenter, DRAPALIN enables physicians to obtain information on this topic quickly, in a professional, well-founded and evidence-based manner. The exclusive awareness campaign includes practice-relevant articles on the mechanism of action, areas of application, patient education and cost coverage. In addition to this comprehensive range of information, a major plus point of this campaign is the professional exchange within a broad network of experts: coliquio offers medical professionals a free platform on which contributions can be discussed directly in topic-specific forums.
The combination of current scientific data and the empirical values of the last years in the medical practice everyday life with medical Cannabis lets hope large potential. The cooperation of the Munich wholesaler with coliquio makes a further decisive contribution to the educational work on the subject of medical cannabis.
DRAPALIN
Drapalin Pharmaceuticals GmbH from Munich is the first and currently the only company to supply medical cannabis from producer MG Health from Lesotho to German pharmacies.
In addition to high-quality products, DRAPALIN focuses on simple ordering processes, a reliable logistics network and comprehensive information for professionals. This includes transparent and open communication regarding the manufacturer, place of origin and production processes.
coliquio is a German-language online expert network specializing in the exchange of knowledge among physicians. Only licensed physicians, dentists and psychological psychotherapists have access. On coliquio, the medical profession finds professional exchange on patient cases, diagnoses and therapy options. Registered members search for experience reports, information on preparations or indications and have access to know-how from pharmaceutical companies. As of the end of 2021, more than 190,000 physicians from all specialties are registered on coliquio. The company’s goal is “dialogue for better medicine”.
DRAPALIN media contact
Lana Korneva
Phone: +49 (89) 277 801 320
Fax: +49 (89) 999 502 44
E-mail: info@drapalin.de
Drapalin Pharmaceuticals GmbH, Paul-Heyse-Str. 28, 80336 Munich, Germany
More information at www.drapalin.de
DRAPALIN uses the genderless generic masculine for better readability of texts. Thus, in accordance with our philosophy, people of all genders are addressed equally.
Based on the materials www.gesundheit-adhoc.de
